Sortilin and Homocysteine as Potential Biomarkers for Coronary Artery Diseases

Purpose: The aim of this study was to assess the relationship of coronary artery disease (CAD) with levels of homocysteine and sortilin in Egyptian patients. Background: CAD is a primary contributor to cardiac disease and a prominent cause of death globally. Patients and Methods: We enrolled 45 patients with CAD evaluated by coronary CT angiography and 42 control subjects without CAD. Plasma-homocysteine and -sortilin levels were measured with a commercial ELISA kit. Results: Elevated levels of homocysteine and sortilin were observed in the CAD patients compared to controls (13.75± 1.40 vs 7.73± 2.06 μmol/L, P =0 and 160.91± 32.17 vs 143.02± 32.30 ng/dL, P =0.02, respectively). Significantly higher total cholesterol, low density–lipoprotein cholesterol and triglycerides ( P < 0.05) and lower high density–lipoprotein cholesterol ( P < 0.05) were seen among patients with CAD than the control group. Sortilin levels were positively associated with homocysteine levels ( r =0.32, P =0.006), total cholesterol ( r =0.61, P =0), low density–lipoprotein cholesterol ( r =0.37, P =0.001), triglycerides ( r =0.91, P =0), troponin I ( r =0.82, P =0), Gensini score ( r =0.93, P =0) and high-sensitivity CRP ( r =0.87, P =0) in all subjects. Homocysteine has a significantly negative association with high density–lipoprotein cholesterol ( r =− 0.42, P =0). Conclusion: Elevated homocysteine and sortilin levels are crucial risk factors of CAD in Egyptian patients.